Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD

Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphi...

Full description

Saved in:
Bibliographic Details
Published inBlood cancer journal (New York) Vol. 11; no. 2; pp. 42 - 12
Main Authors Dai, Hao, Rachakonda, Sivaramakrishna P., Penack, Olaf, Blau, Igor W., Blau, Olga, Radujkovic, Aleksandar, Müller-Tidow, Carsten, Dreger, Peter, Kumar, Rajiv, Luft, Thomas
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 27.02.2021
Springer Nature B.V
Nature Publishing Group
Subjects
692/308/575
692/499
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Health risk assessment
Hematology
Ligands
Morbidity
Mortality
Oncology
Pathogenesis
Stem cell transplantation
Stem cells
Transplants & implants
Online AccessGet full text
ISSN2044-5385
2044-5385
DOI10.1038/s41408-021-00434-2

Cover

Abstract Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9–11 SNPs as well as peri-transplant CXCL9–11 serum levels were analyzed in 688 patients without (training cohort; n  = 287) or with statin-based endothelial protection cohort ( n  = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort ( n  = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33–4.64, P  = 0.004) and validation cohort (HR 2.95, 95% CI 1.56–5.58, P  = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 ( P  < 0.001) and rs884004 ( P  < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10–1.73, P  = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD.
AbstractList Abstract Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9–11 SNPs as well as peri-transplant CXCL9–11 serum levels were analyzed in 688 patients without (training cohort; n = 287) or with statin-based endothelial protection cohort (n = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort (n = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33–4.64, P = 0.004) and validation cohort (HR 2.95, 95% CI 1.56–5.58, P = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 (P < 0.001) and rs884004 (P < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10–1.73, P = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD.
Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9–11 SNPs as well as peri-transplant CXCL9–11 serum levels were analyzed in 688 patients without (training cohort; n  = 287) or with statin-based endothelial protection cohort ( n  = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort ( n  = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33–4.64, P  = 0.004) and validation cohort (HR 2.95, 95% CI 1.56–5.58, P  = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 ( P  < 0.001) and rs884004 ( P  < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10–1.73, P  = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD.
Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9-11 SNPs as well as peri-transplant CXCL9-11 serum levels were analyzed in 688 patients without (training cohort; n = 287) or with statin-based endothelial protection cohort (n = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort (n = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33-4.64, P = 0.004) and validation cohort (HR 2.95, 95% CI 1.56-5.58, P = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 (P < 0.001) and rs884004 (P < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10-1.73, P = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD.Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9-11 SNPs as well as peri-transplant CXCL9-11 serum levels were analyzed in 688 patients without (training cohort; n = 287) or with statin-based endothelial protection cohort (n = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort (n = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33-4.64, P = 0.004) and validation cohort (HR 2.95, 95% CI 1.56-5.58, P = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 (P < 0.001) and rs884004 (P < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10-1.73, P = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD.
Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk of severe cGVHD remains difficult to predict and may involve CXCR3 ligands. This study investigated the role of single-nucleotide polymorphisms (SNPs) of CXCL4, CXCL9, CXCL10, and CXCL11, and their day +28 serum levels, in cGVHD pathogenesis. Eighteen CXCR3 and CXCL4, CXCL9–11 SNPs as well as peri-transplant CXCL9–11 serum levels were analyzed in 688 patients without (training cohort; n = 287) or with statin-based endothelial protection cohort (n = 401). Clinical outcomes were correlated to serum levels and SNP status. Significant polymorphisms were further analyzed by luciferase reporter assays. Findings were validated in an independent cohort (n = 202). A combined genetic risk comprising four CXCR3 ligand SNPs was significantly associated with increased risk of severe cGVHD in both training cohort (hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.33–4.64, P = 0.004) and validation cohort (HR 2.95, 95% CI 1.56–5.58, P = 0.001). In reporter assays, significantly reduced suppressive effects of calcineurin inhibitors in constructs with variant alleles of rs884304 (P < 0.001) and rs884004 (P < 0.001) were observed. CXCL9 serum levels at day +28 after alloSCT correlated with both genetic risk and risk of severe cGVHD (HR 1.38, 95% CI 1.10–1.73, P = 0.006). This study identifies patients with high genetic risk to develop severe cGVHD.
ArticleNumber 42
Author Penack, Olaf
Blau, Igor W.
Dreger, Peter
Dai, Hao
Rachakonda, Sivaramakrishna P.
Radujkovic, Aleksandar
Luft, Thomas
Kumar, Rajiv
Müller-Tidow, Carsten
Blau, Olga
Author_xml – sequence: 1
  givenname: Hao
  surname: Dai
  fullname: Dai, Hao
  organization: Department of Epidemiology, German Cancer Research Centre (DKFZ)
– sequence: 2
  givenname: Sivaramakrishna P.
  surname: Rachakonda
  fullname: Rachakonda, Sivaramakrishna P.
  organization: Department of Epidemiology, German Cancer Research Centre (DKFZ)
– sequence: 3
  givenname: Olaf
  surname: Penack
  fullname: Penack, Olaf
  organization: Division of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin
– sequence: 4
  givenname: Igor W.
  surname: Blau
  fullname: Blau, Igor W.
  organization: Division of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin
– sequence: 5
  givenname: Olga
  surname: Blau
  fullname: Blau, Olga
  organization: Division of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin
– sequence: 6
  givenname: Aleksandar
  surname: Radujkovic
  fullname: Radujkovic, Aleksandar
  organization: Department of Medicine V, University Hospital Heidelberg
– sequence: 7
  givenname: Carsten
  surname: Müller-Tidow
  fullname: Müller-Tidow, Carsten
  organization: Department of Medicine V, University Hospital Heidelberg
– sequence: 8
  givenname: Peter
  orcidid: 0000-0002-7429-8570
  surname: Dreger
  fullname: Dreger, Peter
  organization: Department of Medicine V, University Hospital Heidelberg
– sequence: 9
  givenname: Rajiv
  surname: Kumar
  fullname: Kumar, Rajiv
  organization: Department of Epidemiology, German Cancer Research Centre (DKFZ)
– sequence: 10
  givenname: Thomas
  orcidid: 0000-0002-0387-1640
  surname: Luft
  fullname: Luft, Thomas
  email: Thomas.luft@med.uni-heidelberg.de
  organization: Department of Medicine V, University Hospital Heidelberg
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33640906$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1DAQjVARLaV_gAOKxIVLwN9rX5DQAm2llUB8iZvlOONdrxJ7sbOV9t_jNKW0PdQXj2beezNjv-fVUYgBquolRm8xovJdZpgh2SCCG4QYZQ15Up0QxFjDqeRHd-Lj6iznLSqHC6ywelYdUyoYUkicVN-_xv4wxLTb-Dzk2od6-Xv5jda9X5vQ5XqXoPN2rMGk_jDVVqpOYOMVpENdEHWGEkJtNykGb-vzXxcfX1RPnekznN3cp9XPz59-LC-a1Zfzy-WHVWMFEmMj1AJ3jjlDGXddy7FT3ChmHG6Js85wjolU3BrHuSOE2wUlkrAWccSIUZieVpezbhfNVu-SH0w66Gi8vk7EtNYmjd72oEsrQB1qW8U7JjFTvBWgEFYEpABoi9b7WWu3bwfoLIQxmf6e6P1K8Bu9jld6oTAjHBWBNzcCKf7ZQx714LOFvjcB4j5rwhSTCyEQL9DXD6DbuE-hPNWEorIsiSbBV3cnuh3l398VAJkBNsWcE7hbCEZ68oiePaKLR_S1RzQpJPmAZP1oRh-nrXz_OJXO1Fz6hDWk_2M_wvoL5xHNvA
CitedBy_id crossref_primary_10_1016_j_transproceed_2022_12_012
crossref_primary_10_1016_j_jtct_2022_05_038
crossref_primary_10_1016_j_jtct_2022_07_008
crossref_primary_10_1016_j_trim_2024_102128
crossref_primary_10_3389_fimmu_2021_634416
crossref_primary_10_1007_s00520_023_08044_3
Cites_doi 10.1200/JCO.2017.76.4662
10.1161/01.CIR.0000129502.10459.fe
10.1084/jem.20021897
10.1016/j.bbmt.2010.05.006
10.1097/TP.0b013e3181f2c92b
10.1056/NEJM199907013410103
10.3389/fimmu.2017.01937
10.1038/bmt.2012.210
10.1016/j.critrevonc.2013.03.009
10.1016/j.yexcr.2010.12.017
10.4049/jimmunol.167.12.7084
10.1016/j.bbmt.2016.09.023
10.1182/blood-2008-07-168351
10.1074/jbc.275.1.197
10.1074/jbc.272.38.23597
10.1080/17474086.2019.1605288
10.1155/2013/434586
10.1182/blood-2012-02-413260
10.1016/S0140-6736(02)08907-9
10.1101/gr.139105.112
10.1165/rcmb.2012-0132OC
10.1016/j.bbmt.2014.10.027
10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W
10.1074/jbc.274.43.31102
10.1111/j.1365-2141.2012.09128.x
10.1111/j.1749-6632.2009.04813.x
10.1128/JVI.00202-11
10.1200/JCO.2010.33.7212
10.1093/ndt/gfh385
10.1038/srep28652
10.1200/JCO.2013.54.4056
10.1016/j.beha.2008.03.003
10.1182/blood-2011-01-332478
10.1016/j.bbmt.2005.09.004
10.1371/journal.pone.0006203
10.1016/j.humimm.2019.03.003
10.4049/jimmunol.177.10.6991
10.1038/bmt.2009.346
10.1186/ar1776
10.1016/j.bbmt.2014.10.029
10.1038/bmt.2017.119
10.1016/S0002-9440(10)63776-5
10.1002/eji.200838189
10.1016/j.cytogfr.2010.10.011
10.1016/j.bbmt.2014.10.021
10.1007/s10753-013-9606-2
10.1182/blood-2007-05-091074
10.1016/j.bbmt.2013.10.014
10.1200/JCO.2015.65.9615
10.1038/sj.bjc.6606056
10.1182/blood-2013-07-514372
10.1097/TP.0000000000003108
10.1038/s41409-018-0156-y
10.1002/art.27478
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41408-021-00434-2
DatabaseName Springer Nature OA Free Journals (Selected full-text)
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef

MEDLINE - Academic

Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2044-5385
EndPage 12
ExternalDocumentID oai_doaj_org_article_971e0d0bb95d481495b6e90192e86eeb
PMC7914250
33640906
10_1038_s41408_021_00434_2
Genre Journal Article
GrantInformation_xml – fundername: Deutsche Forschungsgemeinschaft (German Research Foundation)
  grantid: TL820.8-1
  funderid: https://doi.org/10.13039/501100001659
– fundername: EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health)
  grantid: 306240
  funderid: https://doi.org/10.13039/100011272
– fundername: China Scholarship Council (CSC)
  funderid: https://doi.org/10.13039/501100004543
– fundername: Deutsche Forschungsgemeinschaft (German Research Foundation)
  grantid: TL820.8-1
– fundername: EC | EC Seventh Framework Programm | FP7 Health (FP7-HEALTH - Specific Programme "Cooperation": Health)
  grantid: 306240
– fundername: ;
– fundername: ;
  grantid: 306240
– fundername: ;
  grantid: TL820.8-1
GroupedDBID 0R~
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EJD
EMOBN
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
M1P
M48
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
W2D
AASML
AAYXX
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
AARCD
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c606t-6971df4fa345fdb51f95a94af1b2fcfa5512895caf55f225c732824b05042a913
IEDL.DBID M48
ISSN 2044-5385
IngestDate Wed Aug 27 01:15:55 EDT 2025
Thu Aug 21 14:00:22 EDT 2025
Thu Sep 04 23:21:31 EDT 2025
Wed Aug 13 06:44:29 EDT 2025
Thu Jan 02 22:57:09 EST 2025
Tue Jul 01 02:32:59 EDT 2025
Thu Apr 24 22:56:57 EDT 2025
Fri Feb 21 02:38:29 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-6971df4fa345fdb51f95a94af1b2fcfa5512895caf55f225c732824b05042a913
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0387-1640
0000-0002-7429-8570
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41408-021-00434-2
PMID 33640906
PQID 2493882400
PQPubID 2041967
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_971e0d0bb95d481495b6e90192e86eeb
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7914250
proquest_miscellaneous_2494876605
proquest_journals_2493882400
pubmed_primary_33640906
crossref_primary_10_1038_s41408_021_00434_2
crossref_citationtrail_10_1038_s41408_021_00434_2
springer_journals_10_1038_s41408_021_00434_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-02-27
PublicationDateYYYYMMDD 2021-02-27
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-02-27
  day: 27
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
PublicationTitle Blood cancer journal (New York)
PublicationTitleAbbrev Blood Cancer J
PublicationTitleAlternate Blood Cancer J
PublicationYear 2021
Publisher Nature Publishing Group UK
Springer Nature B.V
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
– name: Nature Publishing Group
References Lee, Qin, Benveniste (CR51) 2008; 38
Lacotte, Brun, Muller, Dumortier (CR12) 2009; 1173
Henneken, Dorner, Burmester, Berek (CR43) 2005; 7
Yoon, Lim, Kim, Cho, Min (CR53) 2010; 90
Khoder (CR19) 2017; 8
Alevizopoulos, Dusserre, Ruegg, Mermod (CR34) 1997; 272
Amuro (CR49) 2010; 62
Csanadi (CR6) 2019; 12
CR30
Lasagni (CR16) 2003; 197
Westekemper (CR23) 2010; 45
Fleming (CR21) 2009; 4
Rachakonda (CR47) 2014; 32
Socie (CR1) 1999; 341
Filipovich (CR7) 2005; 11
CR8
Wang (CR37) 2012; 22
Marques (CR44) 2011; 85
Chen (CR9) 2007; 110
Fae (CR38) 2013; 36
Rotta (CR54) 2010; 16
Campanella (CR15) 2006; 177
Sarantopoulos, Blazar, Cutler, Ritz (CR41) 2015; 21
Zeisbrich (CR46) 2017; 52
Amatschek (CR39) 2011; 104
Lentine, Brennan (CR29) 2004; 19
Pratt (CR32) 2013; 48
Vandercappellen, Van Damme, Struyf (CR17) 2011; 22
Yu (CR31) 2016; 34
Nishimori (CR11) 2012; 119
Cooke (CR33) 2017; 23
Sauty (CR13) 2001; 167
Wingard (CR2) 2011; 29
Dignan (CR5) 2012; 158
Loetscher, Loetscher, Brass, Meese, Moser (CR14) 1998; 28
Arai (CR3) 2015; 21
Green (CR20) 2012; 47
Biedermann (CR22) 2002; 359
Akiyama (CR42) 2016; 6
Blaeser, Ho, Prywes, Chatila (CR35) 2000; 275
Mach (CR52) 2004; 109
Theurich (CR55) 2013; 88
Croudace (CR25) 2012; 120
Mao, Wiedmann (CR36) 1999; 274
Ruutu (CR48) 2014; 20
CR26
Rachakonda (CR45) 2018; 36
Sugerman (CR24) 2004; 164
Tyndall, Dazzi (CR4) 2008; 21
Imanguli (CR27) 2009; 113
Jameel (CR50) 2013; 2013
McManigle, Youssef, Sarantopoulos (CR40) 2019; 80
Marini, Choi, Byersdorfer, Cronin, Frame (CR28) 2015; 21
Bruggen (CR10) 2014; 123
Groom, Luster (CR18) 2011; 317
Z Mao (434_CR36) 1999; 274
H Amuro (434_CR49) 2010; 62
AH Filipovich (434_CR7) 2005; 11
F Blaeser (434_CR35) 2000; 275
M Rotta (434_CR54) 2010; 16
A Khoder (434_CR19) 2017; 8
SP Rachakonda (434_CR47) 2014; 32
JN Fleming (434_CR21) 2009; 4
BL Marini (434_CR28) 2015; 21
SJ Lee (434_CR51) 2008; 38
M Henneken (434_CR43) 2005; 7
JR Groom (434_CR18) 2011; 317
F Mach (434_CR52) 2004; 109
GSV Campanella (434_CR15) 2006; 177
CP Marques (434_CR44) 2011; 85
KL Lentine (434_CR29) 2004; 19
SP Rachakonda (434_CR45) 2018; 36
S Amatschek (434_CR39) 2011; 104
434_CR8
S Arai (434_CR3) 2015; 21
FL Dignan (434_CR5) 2012; 158
J Yu (434_CR31) 2016; 34
M Csanadi (434_CR6) 2019; 12
J Wang (434_CR37) 2012; 22
A Tyndall (434_CR4) 2008; 21
A Sauty (434_CR13) 2001; 167
MC Bruggen (434_CR10) 2014; 123
W McManigle (434_CR40) 2019; 80
JR Wingard (434_CR2) 2011; 29
PB Sugerman (434_CR24) 2004; 164
S Sarantopoulos (434_CR41) 2015; 21
H Westekemper (434_CR23) 2010; 45
434_CR30
Y Akiyama (434_CR42) 2016; 6
LA Green (434_CR20) 2012; 47
M Zeisbrich (434_CR46) 2017; 52
S Lacotte (434_CR12) 2009; 1173
J Vandercappellen (434_CR17) 2011; 22
A Alevizopoulos (434_CR34) 1997; 272
KC Fae (434_CR38) 2013; 36
G Socie (434_CR1) 1999; 341
H Nishimori (434_CR11) 2012; 119
LM Pratt (434_CR32) 2013; 48
T Ruutu (434_CR48) 2014; 20
434_CR26
JE Croudace (434_CR25) 2012; 120
MM Imanguli (434_CR27) 2009; 113
HK Yoon (434_CR53) 2010; 90
A Jameel (434_CR50) 2013; 2013
M Loetscher (434_CR14) 1998; 28
KR Cooke (434_CR33) 2017; 23
X Chen (434_CR9) 2007; 110
L Lasagni (434_CR16) 2003; 197
BC Biedermann (434_CR22) 2002; 359
S Theurich (434_CR55) 2013; 88
References_xml – volume: 36
  start-page: 789
  year: 2018
  end-page: 800
  ident: CR45
  article-title: Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.76.4662
– volume: 109
  start-page: II15
  year: 2004
  end-page: II17
  ident: CR52
  article-title: Statins as immunomodulatory agents
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000129502.10459.fe
– volume: 197
  start-page: 1537
  year: 2003
  end-page: 1549
  ident: CR16
  article-title: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20021897
– volume: 16
  start-page: 1463
  year: 2010
  end-page: 1466
  ident: CR54
  article-title: Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2010.05.006
– volume: 90
  start-page: 853
  year: 2010
  end-page: 860
  ident: CR53
  article-title: Effects of pravastatin on murine chronic graft-versus-host disease
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e3181f2c92b
– volume: 341
  start-page: 14
  year: 1999
  end-page: 21
  ident: CR1
  article-title: Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199907013410103
– volume: 8
  start-page: 1937
  year: 2017
  ident: CR19
  article-title: Evidence for B cell exhaustion in chronic graft-versus-host disease
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.01937
– volume: 48
  start-page: 722
  year: 2013
  end-page: 728
  ident: CR32
  article-title: IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2012.210
– volume: 88
  start-page: 178
  year: 2013
  end-page: 186
  ident: CR55
  article-title: Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2013.03.009
– volume: 317
  start-page: 620
  year: 2011
  end-page: 631
  ident: CR18
  article-title: CXCR3 in T cell function
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2010.12.017
– volume: 167
  start-page: 7084
  year: 2001
  end-page: 7093
  ident: CR13
  article-title: CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11)
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.167.12.7084
– volume: 23
  start-page: 211
  year: 2017
  end-page: 234
  ident: CR33
  article-title: The biology of chronic graft-versus-host disease: a task force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2016.09.023
– ident: CR8
– volume: 113
  start-page: 3620
  year: 2009
  end-page: 3630
  ident: CR27
  article-title: Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa
  publication-title: Blood
  doi: 10.1182/blood-2008-07-168351
– volume: 275
  start-page: 197
  year: 2000
  end-page: 209
  ident: CR35
  article-title: Ca(2+)-dependent gene expression mediated by MEF2 transcription factors
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.275.1.197
– volume: 272
  start-page: 23597
  year: 1997
  end-page: 23605
  ident: CR34
  article-title: Regulation of the transforming growth factor beta-responsive transcription factor CTF-1 by calcineurin and calcium/calmodulin-dependent protein kinase IV
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.272.38.23597
– volume: 12
  start-page: 311
  year: 2019
  end-page: 323
  ident: CR6
  article-title: A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease
  publication-title: Expert Rev. Hematol.
  doi: 10.1080/17474086.2019.1605288
– volume: 2013
  start-page: 434586
  year: 2013
  ident: CR50
  article-title: Statin modulation of human T-cell proliferation, IL-1beta and IL-17 production, and IFN-gamma T cell expression: synergy with conventional immunosuppressive agents
  publication-title: Int. J. Inflamm.
  doi: 10.1155/2013/434586
– volume: 120
  start-page: 4246
  year: 2012
  end-page: 4255
  ident: CR25
  article-title: Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD
  publication-title: Blood
  doi: 10.1182/blood-2012-02-413260
– volume: 359
  start-page: 2078
  year: 2002
  end-page: 2083
  ident: CR22
  article-title: Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08907-9
– volume: 22
  start-page: 1798
  year: 2012
  end-page: 1812
  ident: CR37
  article-title: Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors
  publication-title: Genome Res.
  doi: 10.1101/gr.139105.112
– volume: 47
  start-page: 807
  year: 2012
  end-page: 814
  ident: CR20
  article-title: Cigarette smoke-induced CXCR3 receptor up-regulation mediates endothelial apoptosis
  publication-title: Am. J. Respir. Cell Mol. Biol.
  doi: 10.1165/rcmb.2012-0132OC
– volume: 21
  start-page: 809
  year: 2015
  end-page: 820
  ident: CR28
  article-title: Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2014.10.027
– volume: 28
  start-page: 3696
  year: 1998
  end-page: 3705
  ident: CR14
  article-title: Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization
  publication-title: Eur. J. Immunol.
  doi: 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W
– volume: 274
  start-page: 31102
  year: 1999
  end-page: 31107
  ident: CR36
  article-title: Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.274.43.31102
– volume: 158
  start-page: 46
  year: 2012
  end-page: 61
  ident: CR5
  article-title: Diagnosis and management of chronic graft-versus-host disease
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.2012.09128.x
– ident: CR26
– volume: 1173
  start-page: 310
  year: 2009
  end-page: 317
  ident: CR12
  article-title: CXCR3, inflammation, and autoimmune diseases
  publication-title: Ann. NY Acad. Sci.
  doi: 10.1111/j.1749-6632.2009.04813.x
– volume: 85
  start-page: 6136
  year: 2011
  end-page: 6147
  ident: CR44
  article-title: CXCR3-dependent plasma blast migration to the central nervous system during viral encephalomyelitis
  publication-title: J. Virol.
  doi: 10.1128/JVI.00202-11
– volume: 29
  start-page: 2230
  year: 2011
  end-page: 2239
  ident: CR2
  article-title: Long-term survival and late deaths after allogeneic hematopoietic cell transplantation
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2010.33.7212
– volume: 19
  start-page: 2378
  year: 2004
  end-page: 2386
  ident: CR29
  article-title: Statin use after renal transplantation: a systematic quality review of trial-based evidence
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/gfh385
– volume: 6
  year: 2016
  ident: CR42
  article-title: Increased CXCR3 expression of infiltrating plasma cells in hunner type interstitial cystitis
  publication-title: Sci. Rep.
  doi: 10.1038/srep28652
– volume: 32
  start-page: 3421
  year: 2014
  end-page: 3427
  ident: CR47
  article-title: Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2013.54.4056
– volume: 21
  start-page: 281
  year: 2008
  end-page: 289
  ident: CR4
  article-title: Chronic GVHD as an autoimmune disease
  publication-title: Best Pract. Res. Clin. Haematol.
  doi: 10.1016/j.beha.2008.03.003
– volume: 119
  start-page: 285
  year: 2012
  end-page: 295
  ident: CR11
  article-title: Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17
  publication-title: Blood
  doi: 10.1182/blood-2011-01-332478
– volume: 11
  start-page: 945
  year: 2005
  end-page: 956
  ident: CR7
  article-title: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2005.09.004
– volume: 4
  year: 2009
  ident: CR21
  article-title: Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0006203
– volume: 80
  start-page: 393
  year: 2019
  end-page: 399
  ident: CR40
  article-title: B cells in chronic graft-versus-host disease
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2019.03.003
– ident: CR30
– volume: 177
  start-page: 6991
  year: 2006
  end-page: 6998
  ident: CR15
  article-title: Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.177.10.6991
– volume: 45
  start-page: 1340
  year: 2010
  end-page: 1346
  ident: CR23
  article-title: Differential chemokine expression in chronic GVHD of the conjunctiva
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2009.346
– volume: 7
  start-page: R1001
  year: 2005
  end-page: R1013
  ident: CR43
  article-title: Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar1776
– volume: 21
  start-page: 16
  year: 2015
  end-page: 23
  ident: CR41
  article-title: B cells in chronic graft-versus-host disease
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2014.10.029
– volume: 52
  start-page: 1399
  year: 2017
  end-page: 1405
  ident: CR46
  article-title: Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2017.119
– volume: 62
  start-page: 2073
  year: 2010
  end-page: 2085
  ident: CR49
  article-title: Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production
  publication-title: Arthritis Rheum.
– volume: 164
  start-page: 2189
  year: 2004
  end-page: 2202
  ident: CR24
  article-title: Kinetics of gene expression in murine cutaneous graft-versus-host disease
  publication-title: Am. J. Pathol.
  doi: 10.1016/S0002-9440(10)63776-5
– volume: 38
  start-page: 2325
  year: 2008
  end-page: 2336
  ident: CR51
  article-title: The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200838189
– volume: 22
  start-page: 1
  year: 2011
  end-page: 18
  ident: CR17
  article-title: The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2010.10.011
– volume: 21
  start-page: 266
  year: 2015
  end-page: 274
  ident: CR3
  article-title: Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2014.10.021
– volume: 36
  start-page: 800
  year: 2013
  end-page: 811
  ident: CR38
  article-title: CXCL9/Mig mediates T cells recruitment to valvular tissue lesions of chronic rheumatic heart disease patients
  publication-title: Inflammation
  doi: 10.1007/s10753-013-9606-2
– volume: 110
  start-page: 3804
  year: 2007
  end-page: 3813
  ident: CR9
  article-title: Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease
  publication-title: Blood
  doi: 10.1182/blood-2007-05-091074
– volume: 20
  start-page: 135
  year: 2014
  end-page: 138
  ident: CR48
  article-title: Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2013.10.014
– volume: 34
  start-page: 2583
  year: 2016
  end-page: 2590
  ident: CR31
  article-title: Biomarker panel for chronic graft-versus-host disease
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.65.9615
– volume: 104
  start-page: 469
  year: 2011
  end-page: 479
  ident: CR39
  article-title: CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6606056
– volume: 123
  start-page: 290
  year: 2014
  end-page: 299
  ident: CR10
  article-title: Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease
  publication-title: Blood
  doi: 10.1182/blood-2013-07-514372
– volume: 113
  start-page: 3620
  year: 2009
  ident: 434_CR27
  publication-title: Blood
  doi: 10.1182/blood-2008-07-168351
– volume: 85
  start-page: 6136
  year: 2011
  ident: 434_CR44
  publication-title: J. Virol.
  doi: 10.1128/JVI.00202-11
– volume: 104
  start-page: 469
  year: 2011
  ident: 434_CR39
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6606056
– ident: 434_CR30
  doi: 10.1097/TP.0000000000003108
– volume: 22
  start-page: 1
  year: 2011
  ident: 434_CR17
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2010.10.011
– volume: 110
  start-page: 3804
  year: 2007
  ident: 434_CR9
  publication-title: Blood
  doi: 10.1182/blood-2007-05-091074
– volume: 21
  start-page: 809
  year: 2015
  ident: 434_CR28
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2014.10.027
– volume: 28
  start-page: 3696
  year: 1998
  ident: 434_CR14
  publication-title: Eur. J. Immunol.
  doi: 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W
– volume: 48
  start-page: 722
  year: 2013
  ident: 434_CR32
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2012.210
– volume: 47
  start-page: 807
  year: 2012
  ident: 434_CR20
  publication-title: Am. J. Respir. Cell Mol. Biol.
  doi: 10.1165/rcmb.2012-0132OC
– volume: 123
  start-page: 290
  year: 2014
  ident: 434_CR10
  publication-title: Blood
  doi: 10.1182/blood-2013-07-514372
– volume: 167
  start-page: 7084
  year: 2001
  ident: 434_CR13
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.167.12.7084
– volume: 36
  start-page: 800
  year: 2013
  ident: 434_CR38
  publication-title: Inflammation
  doi: 10.1007/s10753-013-9606-2
– volume: 45
  start-page: 1340
  year: 2010
  ident: 434_CR23
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2009.346
– volume: 21
  start-page: 16
  year: 2015
  ident: 434_CR41
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2014.10.029
– volume: 274
  start-page: 31102
  year: 1999
  ident: 434_CR36
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.274.43.31102
– ident: 434_CR8
  doi: 10.1097/TP.0000000000003108
– volume: 90
  start-page: 853
  year: 2010
  ident: 434_CR53
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e3181f2c92b
– volume: 80
  start-page: 393
  year: 2019
  ident: 434_CR40
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2019.03.003
– volume: 359
  start-page: 2078
  year: 2002
  ident: 434_CR22
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08907-9
– volume: 11
  start-page: 945
  year: 2005
  ident: 434_CR7
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2005.09.004
– volume: 1173
  start-page: 310
  year: 2009
  ident: 434_CR12
  publication-title: Ann. NY Acad. Sci.
  doi: 10.1111/j.1749-6632.2009.04813.x
– volume: 275
  start-page: 197
  year: 2000
  ident: 434_CR35
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.275.1.197
– volume: 38
  start-page: 2325
  year: 2008
  ident: 434_CR51
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200838189
– volume: 119
  start-page: 285
  year: 2012
  ident: 434_CR11
  publication-title: Blood
  doi: 10.1182/blood-2011-01-332478
– volume: 21
  start-page: 266
  year: 2015
  ident: 434_CR3
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2014.10.021
– ident: 434_CR26
  doi: 10.1038/s41409-018-0156-y
– volume: 19
  start-page: 2378
  year: 2004
  ident: 434_CR29
  publication-title: Nephrol. Dial. Transplant.
  doi: 10.1093/ndt/gfh385
– volume: 52
  start-page: 1399
  year: 2017
  ident: 434_CR46
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2017.119
– volume: 272
  start-page: 23597
  year: 1997
  ident: 434_CR34
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.272.38.23597
– volume: 2013
  start-page: 434586
  year: 2013
  ident: 434_CR50
  publication-title: Int. J. Inflamm.
  doi: 10.1155/2013/434586
– volume: 177
  start-page: 6991
  year: 2006
  ident: 434_CR15
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.177.10.6991
– volume: 21
  start-page: 281
  year: 2008
  ident: 434_CR4
  publication-title: Best Pract. Res. Clin. Haematol.
  doi: 10.1016/j.beha.2008.03.003
– volume: 22
  start-page: 1798
  year: 2012
  ident: 434_CR37
  publication-title: Genome Res.
  doi: 10.1101/gr.139105.112
– volume: 36
  start-page: 789
  year: 2018
  ident: 434_CR45
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.76.4662
– volume: 197
  start-page: 1537
  year: 2003
  ident: 434_CR16
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20021897
– volume: 62
  start-page: 2073
  year: 2010
  ident: 434_CR49
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.27478
– volume: 16
  start-page: 1463
  year: 2010
  ident: 434_CR54
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2010.05.006
– volume: 317
  start-page: 620
  year: 2011
  ident: 434_CR18
  publication-title: Exp. Cell Res.
  doi: 10.1016/j.yexcr.2010.12.017
– volume: 32
  start-page: 3421
  year: 2014
  ident: 434_CR47
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2013.54.4056
– volume: 4
  year: 2009
  ident: 434_CR21
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0006203
– volume: 120
  start-page: 4246
  year: 2012
  ident: 434_CR25
  publication-title: Blood
  doi: 10.1182/blood-2012-02-413260
– volume: 12
  start-page: 311
  year: 2019
  ident: 434_CR6
  publication-title: Expert Rev. Hematol.
  doi: 10.1080/17474086.2019.1605288
– volume: 6
  year: 2016
  ident: 434_CR42
  publication-title: Sci. Rep.
  doi: 10.1038/srep28652
– volume: 23
  start-page: 211
  year: 2017
  ident: 434_CR33
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2016.09.023
– volume: 341
  start-page: 14
  year: 1999
  ident: 434_CR1
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199907013410103
– volume: 7
  start-page: R1001
  year: 2005
  ident: 434_CR43
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar1776
– volume: 29
  start-page: 2230
  year: 2011
  ident: 434_CR2
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2010.33.7212
– volume: 88
  start-page: 178
  year: 2013
  ident: 434_CR55
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2013.03.009
– volume: 34
  start-page: 2583
  year: 2016
  ident: 434_CR31
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.65.9615
– volume: 8
  start-page: 1937
  year: 2017
  ident: 434_CR19
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.01937
– volume: 109
  start-page: II15
  year: 2004
  ident: 434_CR52
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000129502.10459.fe
– volume: 164
  start-page: 2189
  year: 2004
  ident: 434_CR24
  publication-title: Am. J. Pathol.
  doi: 10.1016/S0002-9440(10)63776-5
– volume: 158
  start-page: 46
  year: 2012
  ident: 434_CR5
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.2012.09128.x
– volume: 20
  start-page: 135
  year: 2014
  ident: 434_CR48
  publication-title: Biol. Blood Marrow Transplant.
  doi: 10.1016/j.bbmt.2013.10.014
SSID ssj0000561919
Score 2.263539
Snippet Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The individual risk...
Abstract Chronic graft-versus-host disease (cGVHD) is a major cause of mortality and morbidity after allogeneic stem cell transplantation (alloSCT). The...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 42
SubjectTerms 692/308/575
692/499
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Health risk assessment
Hematology
Ligands
Morbidity
Mortality
Oncology
Pathogenesis
Stem cell transplantation
Stem cells
Transplants & implants
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NbxMxELVQD1UvCGiBhVK5Um9gdXf9EfsIaUtUtQgBRblZtteGSGFTJemBf8-Md5M2fF64rme11tsZzzyN_UzIkTaiqbRJLHFZMpECZ6YJgUURIVuoRqrcPb98p0ZX4nwsx3eu-sI9YZ08cAfcsRlUsWxK741shMZ63qtosDCJWsXocfWFNHaHTHWq3kAMKtOfkim5Pl4IoBKa4Y4E7H4JVm9koizY_7sq89fNkj91THMiOntA7vcVJH3dzfwhuRfbR2T7su-R75KP72dTIPSA32TxbUEnLR2Ohx84nU6-4LFeej1H0yWNKG2MYxeGIi0Gn_5OwYJCrozzSEMnm0vffh6d7JGrs9NPwxHrr05gARjJkimArUkiOS5karyskpHOCJcqX6eQHNRJwLRkcEnKBCEdULOnFr6UEMTOVPwx2WpnbXxKaErOOR14zY1HMubkwPhgtPAplCaJglQrGG3odcXxeoupzf1trm0HvQXobYbe1gV5uX7nulPV-Kv1G_w7a0tUxM4PwE9s7yf2X35SkP3Vv7V9mC4scE8OFAPWsYIcrochwLBr4to4u8k2QOoU0L6CPOlcYT0TzhXw41IVZLDhJBtT3RxpJ1-ziPfAVLBcwndfrdzpdlp_huLZ_4DiOdmpcxzgwax9srWc38QXUFot_UGOoh9t7xvr
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLxbuBgozEDawmsZ3EJwQLZYUoQkDR3izbsctKS7LdbA_8e2Yc71bLo9d4ojjjGXs-j_0NIc8bJdqiUYEFLnMmguNMtc4xLzysFlUrq5g9P_lUTU_Fh5mcpQ23IR2r3MyJcaJue4d75EcAEzhEg2Byr5bnDKtGYXY1ldC4Tm4UEKqgVdezervHgtGxKlS6K5Pz5mgQACgahucSMAcmWLmzHkXa_n_Fmn8fmfwjbxqXo-PbZD_FkfT1OPB3yDXf3SU3T1Km_B75-rlfAKwHLc6HnwOdd3Qym3zhdDE_w8u9dLlC0TX1SHCMbR8VRXAMlv2LggSFFdOvPHUjeS59_3369j45PX73bTJlqYACc4BL1qxSddEGEQwXMrRWFkFJo4QJhS2DCwaiJcBb0pkgZQDHdsjcUwqbS3Blowr-gOx1fecPCA3BGNM4XnJlEZIZWSvrVCNscLkKIiPFRo3aJXZxLHKx0DHLzRs9ql6D6nVUvS4z8mL7znLk1rhS-g2OzlYSebHjg351ppObafhhn7e5tUq2okH0ZyuvMIz1TeW9zcjhZmx1ctZBX5pWRp5tm8HNMHdiOt9fRBmAdhWAv4w8HE1h2xPOK0DJeZWResdIdrq629LNf0Qq71oVMGnCd19uzOmyW_9XxaOr_-IxuVVGC8eLV4dkb7268E8gdFrbp9E_fgMSsxOU
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals (Selected full-text)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaqIiEuCMor0FZG4gYWcfyIfaSBskIUIaBob5bt2GWlJVvtbg_8e8bOAy0UJK7xWHHGM_Z8mfFnhJ4pzVuqdCSRiZLw6BnRrfck8AC7hWyFzNnzsw9yds7fzcV8D1XjWZhctJ8pLfMyPVaHvdxwQAKKpIKClLziBJbdG6pmNJXxNbKZ_qukiFhTPZyPKZm6puvOHpSp-q-LL_8sk_wtV5q3oNM76PYQO-JX_Wjvor3QHaCbZ0N2_B76_HG1BCgPmltsvm_wosPNvPnE8HJxkQ704st1Et3ikEiNU9t7jRMgBmv-gUECwy4Z1gH7njAXv_06e30fnZ---dLMyHBpAvGARbZE6pq2kUfLuIitEzRqYTW3kboq-mghQgKMJbyNQkRwZp_YeiruSgHuazVlD9B-t-rCI4RjtNYqzyqmXYJhVtTaea24i77UkReIjmo0fmAUTxdbLE3ObDNletUbUL3JqjdVgZ5PfS57Po1_Sp-k2ZkkExd2frBaX5jBNgx8cCjb0jktWq4S4nMy6BS6BiVDcAU6HOfWDA66MYA6GYALWMEK9HRqBtdK-RLbhdVVlgE4JwHwFehhbwrTSBiTgIxLWaB6x0h2hrrb0i2-ZfruWlNYKOG9L0Zz-jWsv6vi8f-JP0G3qmzx6fDVIdrfrq_CEYRPW3ec_eUn9GcRNw
  priority: 102
  providerName: Springer Nature
Title Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD
URI https://link.springer.com/article/10.1038/s41408-021-00434-2
https://www.ncbi.nlm.nih.gov/pubmed/33640906
https://www.proquest.com/docview/2493882400
https://www.proquest.com/docview/2494876605
https://pubmed.ncbi.nlm.nih.gov/PMC7914250
https://doaj.org/article/971e0d0bb95d481495b6e90192e86eeb
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: GX1
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVAQT
  databaseName: Springer Nature - nature.com Journals - Fully Open Access
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: NAO
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.nature.com/siteindex/index.html
  providerName: Nature Publishing
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: M48
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: AAJSJ
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 2044-5385
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000561919
  issn: 2044-5385
  databaseCode: C6C
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELbGJiFeEL_JGJWReINAEttJ_IBQF7ZVFZ2mjaK8WbZjj0ol3dJOYv89ZycpKhQkXhopvjTu5c53Xy_-DqHXOadVnHMbWsKikFpNQl5pHRpqIFqkFUt99Xxymo6mdFyycgf17Y46BS63QjvXT2razN_9uL79CA7_od0ynr9fUkAJeeheNnCFLRrCkrwHkSlxVj7p0v2W6xvggu_1kUSUhuDrrNtHs_1rNmKVp_Tflof--TrlbzVVH6qOH6D7XY6Jh61RPEQ7pn6E7k66KvpjdHG2mAPkBw3Plt-XeFbjoizOCZ7PLt3GX3zVONEVNo782I195tgBZ7D6WwwSGKKpaQzWLbEuPvk6-vQETY-PvhSjsGuuEGrALKsw5VlcWWolocxWisWWM8mptLFKrLYSMinAYkxLy5gFp9eO1SehKmLg5pLH5CnarRe1eY6wtVLKXJOEcOXgmmQZV5rnVFkdcUsDFPdqFLpjHncNMObCV8BJLlrVC1C98KoXSYDerK-5ank3_il96J7OWtJxZvsTi-ZSdC4o4AebqIqU4qyiuUOGKjXcpbgmT41RATron63o7VAAOiUAQmClC9Cr9TC4oKuryNosbrwMwL4UgGGAnrWmsJ4JISkg6CgNULZhJBtT3RypZ988zXfGY1hQ4b5ve3P6Na2_q2L_vxT3At1LvMG7PVoHaHfV3JiXkGWt1ADdycpsgPaGw_HFGI6HR6dn53C2SIuB_-cCPk_KeOBd7CcChyMa
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkIAXxDeBAUaCJ4iWxHYSPyAEHaNj7YRgm_pmHMcelbqktJ1Q_yn-Ru6cpFP52Nte40vinH9n3y9n3xHyIpe8jHPpQsdEFHJnWChLY0LLLawWaSlSHz0fHqT9I_5pJEYb5Fd3Fga3VXZzop-oy9rgP_JtoAkMvEGA3NvpjxCrRmF0tSuh0cBi3y5_AmWbv9nbgfF9mSS7Hw57_bCtKhAacNYXYSqzuHTcacaFKwsROym05NrFReKM0-BCAAkRRjshHKDdYDqbhBeRAHxrGTN47hVylbOIY67-bJSt_umgNy5j2Z7NiVi-PedAYPIQ90FgzI2Hydr658sE_Mu3_XuL5h9xWr_87d4iN1u_lb5rgHabbNjqDrk2bCPzd8nXz_VkeVrDqI3np3M6rmhv1PvC6GR8goeJ6XSGogtqMaEytg0kRTIOlrSkIEFhhbYzS02TrJd-PO7v3CNHl6La-2Szqiv7kFDntNa5YQmTBVJALTJZGJnzwplIOh6QuFOjMm02cyyqMVE-qs5y1ahegeqVV71KAvJqdc-0yeVxofR7HJ2VJObh9hfq2YlqzVrBB9uojIpCipLnyDaL1Ep0m22eWlsEZKsbW9VODnN1DuWAPF81g1ljrEZXtj7zMkAlUyCbAXnQQGHVE8ZSYOVRGpBsDSRrXV1vqcbfferwTMYwScN7X3dwOu_W_1Xx6OKveEau9w-HAzXYO9h_TG4kHu146GuLbC5mZ_YJuG2L4qm3FUq-XbZx_gZZ9k_S
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkCZeEN8EBhgJniBaEttJ_IAQtJSOfWgChvrmxY49KnVJaTuh_mv8ddw5Safysbe91tfWOf_Ovl_ufEfIi1zyMs6lCx0TUcidYaEsjQktt3BapKVIffT84DAdHvNPIzHaIL-6uzCYVtntiX6jLmuD78h3gCYw8AYBcjuuTYs46g_eTn-E2EEKI61dO40GInt2-RPo2_zNbh_W-mWSDD587Q3DtsNAaMBxX4SpzOLScVcwLlypReykKCQvXKwTZ1wB7gQQEmEKJ4QD5BssbZNwHQnAeiFjBr97jVzPGGeYTpaNstX7HfTMZSzbezoRy3fmHMhMHmJOBMbfeJisnYW-ZcC__Ny_0zX_iNn6o3Bwi9xsfVj6rgHdbbJhqztk66CN0t8lX47qyfKshhUcz8_mdFzR3qj3mdHJ-BQvFtPpDEUX1GJxZRzblxSJOVjVkoIEhdPaziw1TeFe-vHbsH-PHF-Jau-Tzaqu7ENCnSuKIjcsYVIjHSxEJrWROdfORNLxgMSdGpVpK5tjg42J8hF2lqtG9QpUr7zqVRKQV6vvTJu6HpdKv8fVWUliTW7_QT07Va2JK3hgG5WR1lKUPEfmqVMr0YW2eWqtDsh2t7aq3Sjm6gLWAXm-GgYTx7hNUdn63MsArUyBeAbkQQOF1UwYS4GhR2lAsjWQrE11faQaf_dlxDMZw4YN__u6g9PFtP6vikeXP8UzsgVmqfZ3D_cekxuJBzve_9omm4vZuX0CHtxCP_WmQsnJVdvmb03EVA0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polymorphisms+in+CXCR3+ligands+predict+early+CXCL9+recovery+and+severe+chronic+GVHD&rft.jtitle=Blood+cancer+journal+%28New+York%29&rft.au=Dai%2C+Hao&rft.au=Rachakonda%2C+Sivaramakrishna+P.&rft.au=Penack%2C+Olaf&rft.au=Blau%2C+Igor+W.&rft.date=2021-02-27&rft.issn=2044-5385&rft.eissn=2044-5385&rft.volume=11&rft.issue=2&rft_id=info:doi/10.1038%2Fs41408-021-00434-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41408_021_00434_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-5385&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-5385&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-5385&client=summon